Navigation Links
EUPROBIO 2008 Presentation to Highlight Latest Immune Research
Date:10/6/2008

Presentation to focus on a new dietary supplement resulting from years of study by leading research scientists in Russia, Ukraine and Bulgaria,

Del-Immune V

BOULDER, Colo., Oct. 6 /PRNewswire/ -- On Thursday, October 16, 2008 at the EUPROBIO 2008 Conference, an abstract entitled "Immune regulatory cytokines Del-Immune V(R) induction and its impact on cytotoxicity of natural killer cells" will be presented to physicians, researchers and educators. Attendees to the presentation will learn about the latest advancements in this field of research. After seeing the study abstract, conference organizers made last-minute changes to the conference schedule to include a presentation of this groundbreaking research.

The abstract is based on a recent study focusing on Del-Immune V(R), a new immunomodulator containing DNA and peptoglycan fragments of lactobacillus rhamnosus V. The study, which confirms that this formulation enhances immune function, was conducted in the Ukraine by several of Europe's foremost research scientists.

Among other findings, the study demonstrated that daily administration of Del-Immune V(R) within 5 days raised a level of circulating interferon up to 4.2+/-0.5 log2 u/ml (P <0.05) against 2.0+/-0.3 log2 u/ml of the controls. Interferons are the switches that help cells resist viral infection and provide the initial, crucial immune response to immune challenges. The results of this latest research demonstrate the immune modulator activity of Del-Immune V(R) and the potential value the dietary supplement may have in clinical situations.

Del-Immune V(R) is a dietary supplement containing a natural culture that starts with healthy bacteria originally found in unpasteurized milk. Unique technological processing of the Del-Immune V(R) formulation creates a natural immunostimulant. The study described above and other research indicates that Del-Immune V(R) could be beneficial in assisting the body in its natural role of protecting the body from germs, viruses and other bodily invaders.

Del-Immune V(R) dietary supplements are produced in the United States. Thousands of people take Del-Immune V(R) on a regular basis and doctors have reported positive results, including an enhanced resistance to cold and flu and a restorative effect on the immune system.

The EUPROBIO 2008 Conference will be held October 15-18, 2008 in Cracow, Poland at Auditorium Maximum.

Contact:

Pamela Sichel

Pure Research Products, LLC

303-530-7761

http://www.delimmune.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Pure Research Products, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strategic Diagnostics Updates Roth Conference Presentation Time
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
4. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
5. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
11. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 23, 2017 , ... BellBrook Labs is formalizing a significant ... of biochemical analyses critical for Lead Discovery. The company’s Lead Discovery Services ... including inhibitor potency and selectivity, mechanism of action, and inhibitor residence times on ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced today ... two key immunotherapy technologies from the University of ... a method to monitor a patient for response ... and CTLA-4.  The second license extends the technology ... is likely to have an immune-related adverse event ...
(Date:2/23/2017)...  Seattle,s upscale Capitol Hill neighborhood, with its swanky shops, parks ... head lice treatment salon to set up shop. But there,s ... a French bistro on E Madison Ave, and CEO ... old lice clinic, we pride ourselves on being a destination ... of the stigma associated with lice. Everyone can get lice ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... (FDA) de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® ... adults at home or in healthcare facilities during periods of rest. A lightweight, ...
Breaking Biology Technology:
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the LEERINK Partners 6th ... Palace Hotel on Wednesday, February 15, 2017 at 10 ... of the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/2/2017)...   TapImmune, Inc. (NASDAQ: ... the development of innovative peptide and gene-based immunotherapeutics ... metastatic disease, announced today it has successfully completed ... second clinical lot of TPIV 200, the company,s ... manufactured vaccine product will be used to supply ...
Breaking Biology News(10 mins):